| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | Muvalaplin | Heart disease | Phase 3 | Trial Planned | Oral | Cardiology |
| Eli Lilly and Company | Mirikizumab - (LUCENT-3) | Ulcerative colitis (UC) | Phase 3 | Data Released | Subcutaneous injection | Gastroenterology |
| Eli Lilly and Company | Tirzepatide - (SURMOUNT-1) | Pre-diabetes and obesity or overweight | Phase 3 | Data Released | Subcutaneous | Endocrinology |
| Eli Lilly and Company | CYRAMZA (ramucirumab) - RAINFALL | First-line gastric cancer | Phase 3 | Intravenous | Oncology | |
| Eli Lilly and Company | RETEVMO (Selpercatinib) - (LIBRETTO-531) | Medullary thyroid cancer (MTC) | Phase 3 | Data Released | Oral | Oncology |
| Eli Lilly and Company | 177Lu-PNT2002 - (SPLASH) | Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Data Released | Intravenous | Oncology |
| Eli Lilly and Company | Orforglipron - (ACHIEVE-4) | Type 2 Diabetes | Phase 3 | Ongoing | Oral | Endocrinology |
| Eli Lilly and Company | MORF-057-202 - (EMERALD-2) | Ulcerative Colitis (UC) | Phase 2b | Ongoing | Oral | Gastroenterology |